What leading analysts look for in a modern CMMS — and what life science leaders can take away

Choosing a CMMS for compliance-heavy life sciences operations is hardly a straightforward purchase. Feature lists blur together, vendors promise similar outcomes, and the final decision often requires input from maintenance, operations, quality, compliance, IT, and finance — sometimes more than a dozen stakeholders 

But sticking with the status quo has its own cost.

Research into predictive maintenance in pharmaceutical manufacturing highlights familiar obstacles for teams evaluating a CMMS for pharmaceuticals: siloed data, limited asset visibility, and inconsistent maintenance practices. Add in paper records, spreadsheets, disconnected systems, and site-by-site workarounds, and it becomes harder to prove what was done, spot recurring issues, standardize PMs, or respond quickly when audit pressure rises. For maintenance teams, that means more manual work and more last-minute scrambling. For leaders, it means less visibility into risk, uptime, labor, and ROI.

The gap: generic CMMS advice vs life sciences’ regulated reality

Life sciences teams — including pharmaceutical manufacturers, biotech companies, medical device manufacturers, diagnostics labs, and research organizations — clearly need more than a system that logs work orders and preventive maintenance scheduling.

They need tools that support regulatory requirements, create consistency across sites, and help protect the business from operational risk. But finding the right fit creates two problems. First, much of the CMMS-buying conversation is too generic for life sciences. It focuses on work orders, assets, dashboards, and automation without necessarily showing whether those capabilities can support validated processes, audit readiness, multi-site governance, or FDA 21 CFR Part 11 and EU GMP Annex 11 expectations.

Second, analyst badges and review-site rankings can help narrow the field, but aren’t always self-explanatory. A strong rating only matters if you understand what the source evaluates — and how those criteria translate into your own maintenance, compliance, and operations requirements.

So how can you decide which platform will actually support the compliance, consistency, and visibility required in regulated operations? The right CMMS should help you modernize maintenance so teams have a better way to anticipate failures, standardize workflows, and demonstrate ROI — without ripping out your ERP.

Here’s what independent analyst firms and review sites prioritize when evaluating CMMS platforms, and how you can use those insights to find a system capable of turning maintenance from a cost center into a driver of operational excellence.

What constitutes a ‘critical capability’ in regulated environments

The average CMMS platforms can help teams log work orders, schedule preventive maintenance, track assets, and report on performance. While valuable in their own right, they’re just the starting point in regulated life sciences environments. A feature that looks useful on paper can fail to reduce risk — and can even create risk — if it does not support validated processes, controlled documentation, multi-site governance, FDA 21 CFR Part 11 and GMP Annex 11 expectations, and the day-to-day realities of maintenance teams working under quality and compliance requirements.

“Other [CMMS] companies just do releases on their own without your input… eMaint told us that when they have a release, we have
the whole quarter to review it and work out any kinks, and then they’d do the validation for you.”

— American Laboratories

That is why buyers in your industry can’t evaluate CMMS as a maintenance tool alone. The hands-on team needs a system that makes work easier, not one that adds clicks, duplicate entry, or rigid workflows that do not match SOPs. At the same time, upper management needs visibility into risk, standardization, uptime, labor efficiency, and ROI. 

The best CMMS bridges that gap: it supports the way technicians actually work and gives leaders the governance and reporting they need to make confident decisions. Here are some of the features to help life sciences organizations accomplish that:

Work orders and PM scheduling
In many environments, work order management and PM scheduling are enough to justify a CMMS. In life sciences, the real question is whether those workflows support complete, traceable records that hold up to audit. Teams need to know what was done, when, by whom, against which asset, and according to which procedure.

Asset tracking and reporting
Asset histories and dashboards are valuable, but leaders in regulated operations need more than maintenance activity reports. They need visibility into operational risk: missed PMs, recurring failures, calibration gaps, site-level inconsistencies, and trends that could affect compliance, uptime, or product quality.

Configurable workflows
Configurability should not mean endless customization or a system that lets every site operate differently. For life sciences teams, the goal is controlled flexibility: workflows that reflect local realities but preserve the standardization needed for SOP adherence, reporting consistency, and inspection preparedness.

Faster ROI
ROI matters, but CMMS is not a magic ROI machine. Value depends on adoption, data quality, process discipline, implementation fit, and whether frontline teams actually use the system as intended. Executives may want fast proof of value, while maintenance teams may worry about disruption. A strong platform has to serve both needs by making adoption practical and outcomes measurable.

The analyst perspective: Where CMMS differences start to matter

With more options than ever, it helps to look at how outside sources evaluate CMMS platforms — not just who earns badges, but what those badges are actually based on.

Analyst firms such as Verdantix assess enterprise asset management and CMMS vendors through structured research on capabilities, market presence, customer needs, and product direction. Customer-review sources such as Gartner Peer Insights and Capterra add a different perspective: how users experience the software in practice, including usability, support, implementation, and day-to-day value.

Taken together, you can used these sources to identify the defining differences between CMMS vendors. For life sciences teams, you’re not just interested in who has the most badges, but whether those recognition map to the critical capabilities needed in regulated operations: multi-site standardization, audit readiness, workflow control, adoption, and measurable time to value.

Questions life science leaders need to ask every vendor

Understanding how analysts evaluate CMMS is only one part of the informed-buyer equation. After all, even the most thorough analyst still works from a point of generality, and your operations will have their own needs, constraints, and risk profile.

But evaluating enterprise software based on vendor sales materials is its own slog. Messaging can sound similar at a high level, feature lists are long, and you’re under pressure to read between the lines: Which platform will actually prove value quickly? Which one will avoid creating new compliance risk? Which one will make work easier instead of adding more?

The wrong CMMS creates more work instead of less, which is why the questions you ask matter. Here are a few things to find out as you evaluate your choices:

Ask: How do you support multi-site governance?
Because: Life sciences organizations often have multiple sites, systems, and inconsistent processes. This inconsistency arises from valid operational needs unique to each site, so you want a CMMS with multi-site deployment to help standardize workflows and centralize reporting, without forcing identical operations.

Ask: How do you support audit readiness?
Because: Audit readiness is not just about having records in the system. When inspection time comes, teams need clear visibility into what was done, where, when, by whom, and against which procedure — along with the traceability and controls expected under cGMP, FDA 21 CFR Part 11, and EU GMP Annex 11. Effective MoC processes help ensure maintenance, asset, and system changes preserve the validated state, while strong reporting and SOP-aligned workflows can support life sciences regulatory compliance by helping reduce last-minute scrambling, lowering the labor required to respond, and making compliance easier to demonstrate.

“The auditor walks through our building with our staff, and the staff scan< the barcode on the asset. By the time they’re back to their desks, we already have the records for them.”
— Landon Smith, Senior Manager of Healthcare Technology Management at Versiti, on using eMaint to generate asset records during audit walkthroughs 

Ask: What implementation model do you recommend? 
Because: There are several approaches to CMMS implementation, each with benefits and tradeoffs. In life sciences, template-based multi-site implementations are often preferred because they accelerate standardization, which in turn makes regulatory compliance easier to achieve and demonstrate. Whatever your preference, your vendor should have the flexibility to recommend the approach that best fits your needs, not lock you into their favored method. 

Ask: How configurable are workflows?
Because: Rigid workflows can create extra work, inconsistent documentation, and reporting gaps across sites. Will the proposed system adapt to your SOPs, forms, and reporting needs or instead box you into the vendor’s process? This difference helps teams adopt readily, standardize what matters, and stay focused on the right data.

Ask: What does success in the first 90 days look like?
Because: No one expects instant results, but for a smooth rollout, early momentum matters. If your vendor offers tailored plans that allow for a flexible timeline and steady user uptake, you can start realizing value without major disruptions, so your maintenance modernization takes months, not years. 

Ask: If you offer AI/predictive tools, how do they meaningfully reduce work or avoid risk?
Because: AI should reduce work, not just add features. In practice, that means it helps teams spot issues earlier, prioritize the right actions, and trigger faster response before failures escalate. The strongest tools turn asset data into actionable recommendations that reduce administrative burden, improve consistency, and avoid unnecessary downtime.

Ask: How will you integrate with our legacy systems?
Because: Replacing your ERP is not always realistic or necessary, and modernizing maintenance should not force a larger systems overhaul than the business is ready for. For life sciences leaders, it’s important to control risk by avoiding disruption to validated processes, limiting added complexity for IT and operations, and improving maintenance without creating friction across the wider business. Avoiding friction applies to existing systems and planning for future needs: does the vendor in question offer supported tools, sensors, and asset data in one ecosystem?

Your regulated CMMS decision checklist

With these insights in hand, ratings and rankings become easier to make sense of, and easier to apply to your own operating reality. Use this checklist as a cheat sheet as you compare vendors and look for a CMMS with a compliance approach that can make life sciences maintenance easier — including the compliance, multi-site management, and ROI pressure that come with it.